STK11 and non-small cell lung carcinoma: In a real-life cohort of advanced NSCLC patients treated with first-line chemotherapy, median OS was shorter in patients with STK11-mutant (n = 288) vs. STK11-WT tumors (n = 1849) (11.2 vs. 17.8 months; HR 1.4 (95%CI 1.2–1.6), p < 0.0001) [48].